Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
QuidelOrtho Corporation filings document an in vitro diagnostics company with Nasdaq-listed common stock under QDEL. Form 8-K disclosures cover quarterly and annual operating results, preliminary revenue estimates, financial guidance, Regulation FD communications and business commentary tied to point-of-care, labs, respiratory, cardiac and immunohematology diagnostics.
The company’s proxy and governance filings address annual meeting matters, board composition, executive compensation and shareholder voting information. Other current reports record leadership transitions, director changes, registered securities information and exhibit-based disclosures furnished with earnings releases and stockholder communications.
QuidelOrtho Corp director Kenneth J. Widder reported routine equity compensation activity involving restricted stock units. On June 6, 2026, he acquired 273 and 910 shares of common stock at $0.00 per share through grants/awards.
These shares came from the release and conversion of previously reported restricted stock units into common stock, with 273 and 910 units exercised at a $0.00 conversion price. Footnotes explain that the restricted stock unit release had been deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors and occurred according to his elected deferral schedule.
QuidelOrtho Corp director Mary Lake Polan, Ph.D. reported compensation-related equity activity involving restricted stock units and common shares. On June 6, 2026, she exercised a total of 973 restricted stock units at $0.00 per unit, each converting into one share of common stock under the company’s program.
These releases were previously reported awards whose delivery was deferred under QuidelOrtho’s deferred compensation program for non-employee directors. Following these transactions, she held 20,442 shares of common stock directly and 17,353 shares indirectly through an LLC. The filing reflects routine director equity compensation rather than open-market buying or selling.
QuidelOrtho Corp director Kenneth F. Buechler increased his direct stake through equity compensation rather than market buying. On June 6, 2026, he acquired 497 and 1,659 shares of Common Stock at $0.00 per share as grants linked to restricted stock units. These 2,156 shares came from the release and conversion of previously reported restricted stock units under QuidelOrtho's deferred compensation program for participating non-employee directors. Following the transactions, Buechler directly owns 110,906 common shares.
QuidelOrtho Corp director Michael Edward L. reported compensation-related equity activity. He received 1,252 shares of common stock through the release and conversion of restricted stock units on June 6, 2026, at a stated price of $0.00 per share as part of his director compensation. Following these awards and conversions, he holds approximately 29,433 common shares directly. Footnotes explain the restricted stock units were previously reported, each unit represents one common share, and their release was deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors.
QuidelOrtho Corp director Matthew Strobeck increased his direct stake through equity compensation. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at $0.00 per share, previously reported as RSUs.
Following this grant and conversion, he holds 34,604 common shares directly. He also reports indirect positions, including 38,145 shares held by Birchview Fund, LLC, where he has sole voting and dispositive power, and 16,630 shares in UGMA accounts for his children, which he disclaims as beneficially owned.
QuidelOrtho Corp director Kenneth J. Widder reported an equity award tied to restricted stock units. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at no cash cost, reflecting a compensation-related grant rather than a market purchase.
Following these transactions, Widder directly holds 43,890 shares of QuidelOrtho common stock. The filing shows an exercise of the corresponding derivative position, leaving no remaining restricted stock units from this grant.
QuidelOrtho Corp director Mary Lake Polan, Ph.D., reported routine equity compensation activity involving restricted stock units and common shares. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at a conversion price of $0.00 per share. These units had been previously reported and each unit represented the right to receive one share of QuidelOrtho common stock. Following the conversion, she held 19,469 shares of common stock directly, while a separate 17,353 shares of common stock were reported as held indirectly through an LLC.
QuidelOrtho Corp director Kenneth F. Buechler reported a compensation-related stock award and vesting of restricted stock units. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at no exercise price. This is reflected as a grant/acquisition of common shares and an exercise of the corresponding restricted stock unit derivative, leaving no units from that grant outstanding. Following these transactions, Buechler directly holds 108,750 shares of QuidelOrtho common stock.
QuidelOrtho Corp director John R. Chiminski reported routine equity compensation activity. On May 29, 2026, restricted stock units vested and were converted into 6,829 shares of Common Stock, reflecting a previously reported award.
Each restricted stock unit represented one share of QuidelOrtho common stock, and the units vested on May 29, 2026. After this grant and corresponding RSU release, Chiminski directly holds 9,352 shares of QuidelOrtho Common Stock, with no remaining position reported in the related RSUs.
QuidelOrtho Corp director R. Scott Huennekens reported a routine equity compensation event. He acquired 6,829 shares of common stock at a stated price of $0.0000 per share through the release of previously granted restricted stock units. These restricted stock units vested on May 29, 2026 and each unit converted into one share of common stock. Following this vesting and conversion, he directly holds 9,352 shares of QuidelOrtho common stock. The filing shows no open-market purchases or sales, only the vesting and exercise of an equity award.